Press Release on the audited (standalone and consolidated) Financial Results for the quarter and year ended March 31, 2026
KRSNAA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Krsnaa Diagnostics reported its highest ever Profit After Tax of ₹1,014 million in FY2026, a 31% growth over the prior year on a consolidated basis. Revenue stood at ₹7,728 million. The PAT figure includes a fair valuation gain of ₹221.75 million from investment in Apulki Healthcare Private Limited, which is a one-time exceptional item. Diluted EPS improved 31% to ₹30.88. Operating cash flows surged 64% to ₹1,431 million from ₹873 million, showing strong improvement in collections and working capital management. The retail diagnostics vertical achieved an 8x revenue jump within 12 months, expanding to 3,500 locations across 5 states. The Board recommended a final dividend of ₹2 per share.
Strong performance with record PAT and 64% jump in operating cash flows is positive for shareholders, though the reported PAT growth is inflated by a one-time fair valuation gain of ₹221.75 million. Investors should note the underlying PAT growth excluding this exceptional item.